홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.1
  1. 홈
  2. /화합물

Sumatriptan Succinate

HCID 59772
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
103628-48-4
표준 SMILES
CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1.O=C(O)CCC(=O)O
InChIKey
PORMUFZNYQJOEI-UHFFFAOYSA-N
분자식
C18H27N3O6S
평균 분자량
413.5 g/mol
단동위원소 질량
413.16205676

개요

Sumatriptan succinate is a succinate salt obtained by reaction of sumatriptan with one equivalent of succinic acid. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used for the acute treatment of migraine with or without aura in adults. It has a role as a serotonergic agonist and a vasoconstrictor agent. It contains a sumatriptan(1+).

이름 및 식별자

우선 이름
Sumatriptan Succinate
IUPAC
butanedioic acid;1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide
영어명
Sumatriptan succinate
분자식
C18H27N3O6S
분자량
413.48848

이름 및 동의어

SUMATRIPTAN SUCCINATE103628-48-4Sumavel DoseProAlsumaOnzetra XsailImitrex StatdoseGR 43175CZembrace SymTouchSumatriptan GalpharmSumatriptan (as succinate)GR-43175CNSC-760362
이름 더 보기
SuMitrexgr43175cSumatriptan succinatSuccinate Sumatriptanmethanesulfonamide(1:1)SumatriptanSuccinate>Penehyclidine Impurity 9SUMATRIPTANSUCCINATE(1:1)SuMatriptan Succinate, EP
J8BDZ68989CHEBI:64359DTXSID60145966ZecuityImigran subjectMigraleve ultraMigraine PackImigran 50

데이터베이스 식별자

CAS
103628-48-4
PubChem CID
59772
DTXSID
DTXSID60145966
ChEMBL
CHEMBL1201150

물성

구조 계산 물성보충 중

극성 표면적
148 Ų
수소 결합 공여자 수
4
수소 결합 수용자 수
8
회전 가능 결합 수
9
무거운 원자 수
28
형식 전하
0
복잡도
498

실험 및 물리화학적 성질

Human Drugs · 3건

Breast Feeding; Lactation; Milk, Human; Serotonin Receptor Agonists; Serotonin 5-HT1 Receptor Agonists; Triptans; Vasoconstrictor Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

물리화학적 성질

녹는점
165 · 165-166°C
저장 조건
-20 °C · -20°C
용해도
2 O: · H2O: >20mg/mL
물리적 상태
고체
색상
흰색에서 황백색까지
Merck
14 · 14,8997
BCS Class
3 · 3
주요 응용
의약품(소분자)
InChI
1S/C14H21N3O2S.C4H6O4/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3;5-3(6)1-2-4(7)8/h4-5,8-9,15-16H,6-7,10H2,1-3H3;1-2H2,(H,5,6)(H,7,8)
InChIKey
PORMUFZNYQJOEI-UHFFFAOYSA-N
SMILES
OC(=O)CCC(O)=O.CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1

화학적 성질

White Crystalline Powder

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H318 (79.6%): Causes serious eye damage [Danger Serious eye damage/eye irritation]

P203, P264+P265, P273, P280, P305+P354+P338, P317, P318, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 54 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Regulatory InformationSumatriptan succinate: Does not have an individual approval but may be used under an appropriate group standard
Hazard Classes and CategoriesEye Dam. 1 (79.6%)

독성 정보

Exposure RoutesSubcutaneous, Oral, Nasal, Transdermal
Toxicity Summary · 1건

The 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors function as autoreceptors, which inhibit the firing of serotonin neurons and a reduction in the synthesis and release of serotonin upon activation. After sumatriptan binds to these receptors, adenylate cyclase activity is inhibited via regulatory G proteins, incrases intracellular calcium, and affects other intracellular events. This results in vasoconstriction and inhibtion of sensory nociceptive (trigeminal) nerve firing and vasoactive neuropeptide release. Sumatriptan stimulates 5-HT receptors of the 1D subtype, most likely presynaptic receptors, resulting in selective vasoconstriction of inflamed and dilated cranial blood vessels in the carotid circulation. Sumatriptan also blocks the release of vasoactive neuropeptides from perivascular trigeminal axons in the dura mater during migraine and may inhibit the release of inflammatory mediators from the trigeminal nerve.

Signs and Symptoms

화학 및 산업

약리 정보

Metabolism/Metabolites · 1건

Hepatic. In vitro studies with human microsomes suggest that sumatriptan is metabolized by monoamine oxidase (MAO), predominantly the A isoenzyme. Route of Elimination: Only 3% of the dose is excreted in the urine as unchanged sumatriptan; 42% of the dose is excreted as the major metabolite, the indole acetic acid analogue of sumatriptan. Half Life: 2.5 hours

FDA Pharmacological Classification · 2건

SUMATRIPTAN SUCCINATE

Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]; Serotonin 1d Receptor Agonists [MoA]; Serotonin 1b Receptor Agonists [MoA]

MeSH Pharmacological Classification · 2건

Drugs used to cause constriction of the blood vessels.

Endogenous compounds and drugs that specifically stimulate SEROTONIN 5-HT1 RECEPTORS. Included under this heading are agonists for one or more of the specific 5-HT1 receptor subtypes.

용도 및 제조

UsesFor the treatment of migraine attacks with or without aura.
응용 분야 · 2건

개요Sumatriptan succinate is a highly selective 5HT1-like receptor agonist introduced as a new treatment for migraine. It is indicated for the acute relief of migraine and cluster headache. Oral administration is reported to be free of substantial side effects. The compound appears to be a significant advance over the use of ergotamine and other agents in the treatment of migraine.

용도Sumatriptan Succinate is a selective 5-HT1B/1D-receptor agonist with anticonvulsant properties (1,2). Sumatriptan Succinate is used for migraine relief (2).

상·하류 제품 정보

상류 원료

관련 반응

2건
반응 기록 만들기
HRID 1625661 반응식
HRID 1625661반응물로uspto-grants-2014_07
HRID 1797389 반응식
HRID 1797389생성물로uspto-grants-2006_04

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
ChEBI
CHEBI:64359
UNII
J8BDZ68989
EC Number
600-463-4
Symptoms of overdose include convulsions, tremor, paralysis, inactivity, ptosis, erythema of the extremities, abnormal respiration, cyanosis, ataxia, mydriasis, salivation, and lacrimation.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Sumatriptan succinate

Ambiguous-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

안전 데이터

wgk
3
rtecs
EJ9940000
ridadr
3077
HS 번호
29350090
risk_code
36/37/38-41
hazard_code
Xi
safety_code
26-36-39
Hazard Classifications
Aquatic Chronic 3Repr. 2
스토리지 클래스
11 - Combustible Solids
4-Hydrazino-N-Methyl Benzene Methane Sulphonamide Hydrochloride

하류 제품

Sumatriptan
추가 설명 · 1건

정의ChEBI: A succinate salt obtained by reaction of sumatriptan with one equivalent of succinic acid. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used for the acute treatm nt of migraine with or without aura in adults.